David W. Cescon
Researcher Next ID · RN-042644
Researcher · Biochemistry, Genetics and Molecular Biology
Toronto, New Zealand
- Works count
- 430
- Citation count
- 15,249
- H-index
- 56
- i10-index
- 145
Research interests
Publications
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.00920
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.00920
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-18020-8
Circulating tumor DNA and liquid biopsy in oncology
Nature Cancer · 2020 · https://doi.org/10.1038/s43018-020-0043-5
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32531-9
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
Nature Communications · 2017 · 10.1038/ncomms14432
Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2008.16.5456
Current projects
No projects listed.